Drug
Pegylated Liposomal Doxorubicin
Pegylated Liposomal Doxorubicin: highest development phase Phase 3, developed by Johnson & Johnson. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Johnson & Johnson
Trials
| Drug | Phase | Indication |
|---|---|---|
| Pegylated liposomal doxorubicin NCT00082095 | Phase 3 | Metastatic Breast Cancer |
Latest
No recent events.
Follow Pegylated Liposomal Doxorubicin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.